[go: up one dir, main page]

AU5142899A - Immobilized labeling compounds and methods - Google Patents

Immobilized labeling compounds and methods

Info

Publication number
AU5142899A
AU5142899A AU51428/99A AU5142899A AU5142899A AU 5142899 A AU5142899 A AU 5142899A AU 51428/99 A AU51428/99 A AU 51428/99A AU 5142899 A AU5142899 A AU 5142899A AU 5142899 A AU5142899 A AU 5142899A
Authority
AU
Australia
Prior art keywords
conjugate
support
methods
metal
labeling compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51428/99A
Other languages
English (en)
Inventor
Linda Fung Ling Lu
Alfred Pollak
Catherine Michelle Pollock
David Roe
John Thornback
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resolution Pharmaceuticals Inc
Original Assignee
Resolution Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resolution Pharmaceuticals Inc filed Critical Resolution Pharmaceuticals Inc
Publication of AU5142899A publication Critical patent/AU5142899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Coupling Device And Connection With Printed Circuit (AREA)
  • Catching Or Destruction (AREA)
  • Electrophonic Musical Instruments (AREA)
AU51428/99A 1999-02-17 1999-08-03 Immobilized labeling compounds and methods Abandoned AU5142899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12056199P 1999-02-17 1999-02-17
US60120561 1999-02-17
PCT/CA1999/000700 WO2000048639A1 (fr) 1999-02-17 1999-08-03 Composes de marquage immobilises et methodes afferentes

Publications (1)

Publication Number Publication Date
AU5142899A true AU5142899A (en) 2000-09-04

Family

ID=22391115

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51428/99A Abandoned AU5142899A (en) 1999-02-17 1999-08-03 Immobilized labeling compounds and methods

Country Status (8)

Country Link
US (1) US7320784B1 (fr)
EP (1) EP1154803B1 (fr)
JP (1) JP2002537274A (fr)
AT (1) ATE282435T1 (fr)
AU (1) AU5142899A (fr)
CA (1) CA2362860A1 (fr)
DE (1) DE69922052T2 (fr)
WO (1) WO2000048639A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
EP2286843A3 (fr) * 2000-06-02 2011-08-03 Bracco Suisse SA Composés pour le ciblage de cellules endothéliales
JP2004517050A (ja) * 2000-09-19 2004-06-10 ユニバーシティ オブ トロント Ｉａｐｐ原線維形成の抑制剤およびそれらの使用
US7687145B2 (en) * 2004-10-04 2010-03-30 The Regents Of The University Of California Compounds containing a thiol protected group bonded to a protecting group via a polarized bond, and structure comprising the compounds on its surface
IL312404A (en) 2017-01-30 2024-06-01 Regeneron Pharma Preparations and methods for reducing biological load in chromatography

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131816C (fr) 1992-03-13 2001-08-28 Richard T. Dean Peptides marques au technetium-99 pour visualiser les inflammations
DE69408145T2 (de) * 1993-07-19 1998-09-03 Resolution Pharm Inc Hydrazine mit einer n3s konfiguration als radionukleide chelatoren
DE69434810T2 (de) 1993-11-16 2007-08-02 Bracco International B.V. Immobilisiertes markierungsverfahren
US5662885A (en) * 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
AU5445196A (en) 1995-05-17 1996-12-11 Minnesota Mining And Manufacturing Company Independently tensioned dual unwind and take-up mechanism us ing a common shaft mounting
US6027711A (en) * 1995-06-07 2000-02-22 Rhomed Incorporated Structurally determined metallo-constructs and applications
DE69840647D1 (de) * 1997-04-22 2009-04-23 Curator Of The University Of M Konjugate aus peptiden, die liganden von gastrinrezeptoren sind
EP1056773A2 (fr) * 1998-02-11 2000-12-06 Resolution Pharmaceuticals Inc. Molecules ciblant l'angiogenese
DK1154991T3 (da) * 1999-02-18 2004-11-22 Univ California Salicylamid-lanthanidkomplekser til anvendelse som luminescerende markörer

Also Published As

Publication number Publication date
US7320784B1 (en) 2008-01-22
WO2000048639A1 (fr) 2000-08-24
DE69922052D1 (de) 2004-12-23
EP1154803A1 (fr) 2001-11-21
ATE282435T1 (de) 2004-12-15
JP2002537274A (ja) 2002-11-05
CA2362860A1 (fr) 2000-08-24
EP1154803B1 (fr) 2004-11-17
DE69922052T2 (de) 2005-06-16

Similar Documents

Publication Publication Date Title
AU2002331422A1 (en) Label with removable portion
AU2001285415A1 (en) System and process for updating electronic messaging accounts
AU1966801A (en) Secure and recoverable database for on-line value-bearing item system
AU2002214749A1 (en) Methods for downhole waveform tracking and sonic labeling
EP0986041A3 (fr) Feuille d'étiquettes avec détachement sélectif
AU3704200A (en) Viability assay for sporocyst-forming protozoa
AU2403901A (en) Maturation-promoting agent for immature dendritic cells
AU3874900A (en) Enzymatic reductions with dihydrogen via metal catalyzed cofactor regeneration
AU8137694A (en) Immobilized labelling method
AU5142899A (en) Immobilized labeling compounds and methods
WO2002072869A3 (fr) Nouveaux agents de remplacement du systeme de nicotinamide adenine dinucleotide (nad+)/nicotinamide adenine dinucleotide hydrogene (nadh) dans des reactions enzymatiques
AU1278801A (en) Method for generating information related to the molecular structure of a biomolecule
AU2002217241A1 (en) Automatic label affixing station
AU3457300A (en) Substrates for thioredoxin reductase
AUPP939499A0 (en) Process for recovering metal values
WO2002101177A3 (fr) Garde-corps pour face
AU6511399A (en) Methods and organisms for concentrating and recovering metals and minerals from aqueous media
AU5451399A (en) Method and device for affixing appendixes to objects
AU4979800A (en) System and method for effectuating electronic payments
AU7552200A (en) Method and device for unified messaging
GB9929674D0 (en) Protease-activated receptor (PAR) modulator assays
AU7030100A (en) Method and apparatus for multi-currency funds settlement
AUPQ299299A0 (en) Method and means for assaying precious metals
EP0840271A3 (fr) Procédé d'étiquettage
AU2001295573A1 (en) Labeling method and corresponding device

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase